Adenosine A(2a) receptors increase arterial endothelial cell nritric oxide

Journal of Surgical Research

Volumn 80, Issue 2, 1998, Pages 357-364

  Li, Jian Ming ^a   Fenton, Richard A ^a   Wheeler, H Brownell ^a   Powell, Craig C ^a   Peyton, Brian D ^a   Cutler, Bruce S ^a   Dobson Jr , James G ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Adenosine; Arterial endothelial cells; Human; Nitric oxide; Porcine

Indexed keywords

2 CHLORO 6 N CYCLOPENTYLADENOSINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; 1,3-DIPROPYL-8-CYCLOPENTYLXANTHINE; 2 CHLORO N(6)CYCLOPENTYLADENOSINE; 2-CHLORO-N(6)CYCLOPENTYLADENOSINE; 9 CHLORO 2 (2 FURYL) (1,2,4)TRIAZOLO(1,5 C)QUINAZOLIN 5 IMINE; 9-CHLORO-2-(2-FURYL)-(1,2,4)TRIAZOLO(1,5-C)QUINAZOLIN-5-IMINE; ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR; DRUG DERIVATIVE; PHENETHYLAMINE DERIVATIVE; QUINAZOLINE DERIVATIVE; TRIAZINE DERIVATIVE; TRIAZOLE DERIVATIVE; XANTHINE DERIVATIVE;

ARTERY ENDOTHELIUM; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; ENZYME INHIBITION; HEART FUNCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR SENSITIVITY; RECEPTOR UPREGULATION; VASODILATATION; ANIMAL; BIOSYNTHESIS; CAROTID ARTERY; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ILIAC ARTERY; METABOLISM; SWINE; VASCULAR ENDOTHELIUM;

ADENOSINE; ADENOSINE-5'-(N-ETHYLCARBOXAMIDE); ANIMALS; CAROTID ARTERIES; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; ILIAC ARTERY; NITRIC OXIDE; PHENETHYLAMINES; QUINAZOLINES; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; SWINE; TRIAZINES; TRIAZOLES; XANTHINES;

EID: 0032217103     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1998.5439     Document Type: Article

References (38)

1. Berne R. M. The role of adenosine in the regulation of coronary blood flow. Circ. Res. 47:1980;807.
2. Dobson J. G. Jr. Circ. Res. 52:1983;151.
3. 2+. Am. J. Physiol. 261:1991;C1107.
4. Fenton R. A., Dobson J. G. Jr. Adenosine and calcium alter adrenergic-induced intact heart protein phosphorylation. Am. J. Physiol. 246:1984;H559.
5. i. Sec. Mess. Phosphoproteins. 12:1988;29.
6. 2a. Cardiovasc. Res. 34:1997;337.
7. Erion M. D. Adenosine receptors as pharmacological targets. Annu. Rev. Med. Chem. 28:1993;295.
8. Olah M. E., Stiles G. L. Adenosine receptor subtypes: Characterization and therapeutic regulation. Annu. Rev. Pharmacol. Toxicol. 35:1995;581.
9. Tucker A. L., Linden J. Cloned receptors and cardiovascular responses to adenosine. Cardiovasc. Res. 27:1993;62.
10. Dobson J. G. Jr., Fenton R. A. Antiadrenergic effects of adenosine in the heart. Regulatory Function of Adenosine. 1983;Nijhoff, Boston. p. 363-376.
11. Belardinelli L., Linden J., Berne R. M. The cardiac effects of adenosine. Prog. Cardiovasc. Dis. 32:1989;73.
12. Burnstock, G. A basis for distinguishing two types of purinergic receptor, L. BolisR. W. Straub, Cell and Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach, New York, Raven Press, 1978, 107, 118.
13. Rice P. J., Armstrong S. C., Ganote C. E. Concentration-response relationships for adenosine agonists during preconditioning of rabbit cardiomyocytes. J. Mol. Cell. Cardiol. 28:1996;1355.
14. Furchgott R. F., Zawadzki J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373.
15. Furchgott R. F., Cherry P. D., Zawadzki J. V. Endothelial cells as mediators of vasodilation of arteries. J. Cardiovasc. Pharmacol. 6:1984;S336.
16. Ignarro L. J., Buga G. M., Wood K. S., Byrns R. E. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA. 84:1987;9265.
17. Moncada S., Herman A. G., Vanhoutte P. Endothelium-derived relaxing factor is identified as nitric oxide. Trends Pharmacol. Sci. 8:1987;365.
18. 2. Br. J. Pharmacol. 109:1993;424.
19. Li J., Fenton R. A., Cutler B. S., Dobson J. G. Jr. Adenosine enhances nitric oxide production by vascular endothelial cells. Am. J. Physiol. 269:1995;C519.
20. Li J., Hajarizadeh H., LaRosa C. A., Rohrer M. J., Vander Salm T. J., Cutler B. S. Heparin and protamine stimulate the production of nitric oxide. J. Cardiovasc. Surg. 37:1996;445.
21. Tsukahara H., Gordienko D. V., Goligorsky M. S. Continuous monitoring of nitric oxide release from human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 193:1993;722.
22. Taha Z., Kiechle F., Malinski T. Oxidation of nitric oxide by oxygen in biological systems monitored by porphyrinic sensor. Biochem. Biophys. Res. Commun. 188:1992;734.
23. 3. Mol. Pharmacol. 29:1986;331.
24. 2. J. Pharmacol. Exp. Ther. 265:1993;248.
25. 2. Eur. J. Pharmacol. 281:1995;9.
26. Ethier M. F., Chander V., Dobson J. G. Jr. Adenosine stimulates proliferation of human endothelial cells in culture. Am. J. Physiol. 265:1993;H131.
27. Ethier M. F., Dobson J. G. Jr. Adenosine stimulation of DNA synthesis in human endothelial cells. Am. J. Physiol. 272:1997;H1470.
28. Steinhorn R. H., Morin F. C., Van Wylen D. G. L., Gugino S. F., Giese E. C., Russell J. A. Endothelium-dependent relaxations to adenosine in juvenile rabbit pulmonary arteries and veins. Am. J. Physiol. 266:1994;H2001.
29. Abebe W., Makujina S. R., Mustafa S. J. Adenosine receptor-mediated relaxation of porcine coronary artery in presence and absence of endothelium. Am. J. Physiol. 266:1994;H2018.
30. 2. Naunyn-Schmiedeberg's Arch. Pharmacol. 336:1987;94.
31. 6. J. Pharmacol. Exp. Ther. 270:1994;893.
32. Abebe W., Hussain T., Olanrewaju H., Mustafa S. J. Role of nitric oxide in adenosine receptor-mediated relaxation of porcine coronary artery. Am. J. Physiol. 269:1995;H1672.
33. +. J. Physiol. 499:1997;135.
34. 2. J. Pharmacol. Exp. Ther. 251:1989;47.
35. Ghai G., Francis J. E., Williams M., Dotson R. A., Hopkins M. F., Cote D. T., Goodman F. R., Zimmerman M. B. Pharmacological characterization of CGS15943A: A novel nonxanthine adenosine antagonist. J. Pharmacol. Exp. Ther. 242:1987;784.
36. 2a. Br. J. Pharmacol. 115:1995;1096.
37. 1. Naunyn-Schmiedeberg's Arch. Pharmacol. 340:1989;679.
38. 12. Eur. J. Pharmacol. 190:1990;329.